CEO Paul Brennan said; “We welcome the opportunity to work with Al Mofadaly to expand our reach throughout the middle-east. Our NovoSorb BTM will offer patients in the region a significant improvement in their clinical outcomes and enable us to serve our global key opinion leaders”.
Ho ho ho
Ann: NovoSorb BTM approved for sale in Saudi Arabia, page-2
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.57 |
Change
0.030(1.18%) |
Mkt cap ! $1.773B | |||
| Open | High | Low | Value | Volume |
| $2.60 | $2.60 | $2.55 | $1.327M | 514.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2507 | $2.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.58 | 4000 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |